Krystal Biotech, Inc.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Krystal Biotech, Inc.
EU Accelerated Assessment Tracker
Pharming’s leniolisib has lost its accelerated assessment status at the European Medicines Agency while Krystal Biotech’s beremagene geperpavec will be fast-tracked once a filing has been made.
EU Fast Track Sought For Epidermolysis Bullosa Gene Therapy & Bispecific RRMM Drug
Janssen and Krystal Biotech will soon learn whether the European Medicines Agency considers their respective products to be of potential major public health interest, particularly from the point of view of therapeutic innovation.
Keeping Track: Axsome’s Auvelity Survives Long Review; Bluebird’s Zynteglo Cleared For Liftoff; Omeros Appeals CRL
The latest drug development news and highlights from the Pink Sheet’s US FDA Performance Tracker
Newly Launched Replay Has Big Plans For Writing and Delivering ‘Big DNA’
With a hub-and-spoke model, Replay has ambitious plans to solve multiple problems in genetic medicine and to disrupt the current AAV gene therapy model.
- Topical Delivery
- Drug Delivery
- Gene Therapy, Cell Therapy
- Large Molecule
- Other Names / Subsidiaries
- Jeune, Inc.
- Jeune Aesthetics, Inc.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.